Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — Investor Presentation (March 2024)
30 slides from Microba Life Sciences's investor presentation, Mar 13, 2024
Slide 1: MetaPanel Australian Launch Presentation
MetaPanel Australian Launch Presentation ASX: MAP 13 March 2024 Authorised for release by the Board of Directors
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 3: Microba is a Medical Diagnostic and Clinical Stage Therapeutics Company
Microba is a Medical Diagnostic and Clinical Stage Therapeutics Company • Microba was founded in late 2017 on world-leading metagenomic microbial genomic and microbiome analysis technology • A clear vision for routine use of diagnostic metagenomic testing, and novel drugs developed using this techno
Slide 4: Microba's evolution into a medical diagnostic and clinical stage therapeutics company
Microba’s evolution into a medical diagnostic and clinical stage therapeutics company Agreement with Agreement with Insert Europe’s largest global medical Insight non-diagnostic medical diagnostics Laboratory receives diagnostics leader MetaXplore MetaPanel test launched directly company SYNLAB. NAT
Slide 5: Microba Testing Business
Microba Testing Business Next generation gastrointestinal diagnostics 5
Slide 6: Next generation gastrointestinal diagnostic tests
Next generation gastrointestinal diagnostic tests Gastrointestinal pathogen test Gastrointestinal disorder test One sample. 7 functional GI markers. 175 targets. >28k microbiome markers. Expertly curated clinical Expertly curated clinical recommendations for recommendations for targeted treatment. p
Slide 7: Patient pathway — Advancing the standard of care for GI symptoms
Patient pathway — Advancing the standard of care for GI symptoms Is it a pathogen Is this a functional Patient presents with causing these Is there risk of GI disorder or mental GI symptoms. IBD or CRC? health disorder? symptoms? IBD risk test faecal If negative IBS Diagnosis by exclusion calprotect
Slide 8: Patient pathway — Advancing the standard of care for GI symptoms
Patient pathway — Advancing the standard of care for GI symptoms Functional microbiome Colonoscopy for formal Targeted antibiotic and or GI disorder diagnosis IBD or CRC diagnosis DGBI treatment /or with personalised New Microba and treatment treatment plan care pathway If positive If positive Expec
Slide 9: MetaPanel: A paradigm shift in GI pathogen diagnosis
MetaPanel A paradigm shift in GI pathogen diagnosis 9
Slide 10: MetaPanel Metagenomic GI pathogen assay
DOUGLASS HANLY MOIR ANE CITIZEN PATHOLOGY 0.0 serwesr | Boe nO 0046 Faroe MetaPanel™ Metagenomic GI pathogen assay Anew approach for diagnosing gastrointestinal infections MetaPanel™ © hiicrobiomics One test. 175 answers. eA ES ronnie MiCROBA
Slide 11: Introduction to MetaPanel
Introduction to MetaPanel • World-first NATA accredited test available exclusively through Sonic Healthcare across Australia • Comprehensive gastrointestinal (GI) pathogen test • A paradigm shift in GI pathogen diagnosis detecting both common and difficult-to-identify pathogens capable of causing in
Slide 12: The MetaPanel opportunity
The MetaPanel opportunity • Infections from a gastrointestinal pathogen are highly prevalent. • Est. >17 million cases of gastrointestinal pathogen illness in Australia alone, every year. • People get infected from food, water, person-to-person, and the environment. • A standard diagnostic test can
Slide 13: ~1 million stool multiplex PCR tests ordered in Australia every year
~1 million stool multiplex PCR tests ordered in Australia to diagnose GI pathogens every year 13
Slide 14: The MetaPanel advantage for doctors and patients
The MetaPanel advantage for doctors and patients • Confidently diagnose or rule out a pathogen. In clinical samples tested by MetaPanel* o 1 in 3 identify an additional potential pathogen undetected by multiplex PCR o 1 in 3 identify an antimicrobial resistance gene that may add additional treatment
Slide 15: The technology
M eta Pa ne [ tetagenomic Gl pathogen assay featrHcare | MiCROBA The technology MICROBA 15
Slide 16: Complex data made simple for the clinician and patient
Complex data made simple for the clinician and patient One sample Processed in Microba’s state of the art Next Generation DNA sequencing laboratory Each MetaPanel sample generates Analysed using Microba’s proprietary ~7,000 books worth of genetic code data* metagenomic technology Test result
Slide 17: Nationwide launch with Sonic Healthcare
Nationwide launch with Sonic Healthcare Starting today 17
Slide 18: Launch events
Launch events • NSW – Douglass Hanly Moir 13th March • VIC – Melbourne Path. 21st March • SA – Clinpath Path. 26th March • TAS – Hobart Path. 26th March • TAS – Launceston Path. 27th March • QLD – Sullivan Nicolaides Path. 16th April • WA – Clinipath/Bunbury Path. 17th April 18
Slide 19: Key Takeaways
Key Takeaways 1. Large patient population being underserved by current testing. 2. MetaPanel is a step-change in technology – no major innovation in this category since 1990s. 3. Most comprehensive GI pathogen test available – existing tests cover up to 22 targets, MetaPanel covers 175 targets in a
Slide 20: Appendix
Appendix MiCROBA
Slide 21: MetaPanel Clinical Validation
MetaPanel Clinical Validation 21
Slide 22: Clinical performance validation studies
Clinical performance validation studies Douglass Hanly Moir Cohort Study Mater Pathology Cohort Study • 588 patient samples • 362 patient samples • Age range 4m to 104 • Age range was >18 years old • 160 (27%) from patients <18 • Subset of positive and negative samples curated from • Standard of car
Slide 23: Strong diagnostic performance
Strong diagnostic performance Highly specific assay that enables confident diagnosis Diagnostic Performance Confidence Measure vs standard of care Sensitivity 0.94 +/- 0.07 Ability of a test to identify the presence of a target correctly; (= TP / (TP + FN)) Specificity 1.00 +/- 0.01 Ability of a tes
Slide 24: What does MetaPanel detect?
What does MetaPanel detect? 24
Slide 25: Pathogen targets
Pathogen targets Bacteria Fungi Helminths Protozoa Aeromonas caviae* Helicobacter pylori Candida auris Ancylostoma duodenale Cryptosporidium felis Aeromonas dhakensis* Listeria monocytogenes Histoplasma capsulatum Ascaris lumbricoides Cryptosporidium hominis/ Aeromonas hydrophila* Neisseria gonorrho
Slide 26: Virulence factors and antimicrobial resistance gene targets
Virulence factors and antimicrobial resistance gene targets Virulence Factors Antimicrobial Resistance Binary toxin/CDT Staphylococcus enterotoxin H armA blaSHV_E240K mcr-4 Cholera toxin Toxin A C. difficile blaACC blaSHV_G238S mcr-5 Clostridium perfringens enterotoxin Toxin A&B C. difficile blaACT
Slide 27: Faeces collection MetaPanel
MiCROBA Faeces collection MetaPanel™ 27
Slide 28: Microba summary
Microba summary MiCROBA
Slide 29: Two core business segments driven by a world leading technology
Two core business segments driven by a world leading technology World leading microbiome analysis technology Testing Business Proprietary databank Therapeutics Business Next generation gastrointestinal diagnostics Advanced AI and biostatistics powering a diagnostics and Precision microbiome therapeu
Slide 30: Contact
Dr Luke Reid CONTACT Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Chairman Princess Alexandra Hospital pasquale.rombola@microba.com Woolloongabba QLD Australia
Microba Life Sciences — Investor Presentation (March 2024) on 6ix